UK markets close in 4 hours 49 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.3215-0.0060 (-1.83%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3275
Open0.3300
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3020 - 0.3300
52-week range0.2300 - 2.5400
Volume814,268
Avg. volume2,381,780
Market cap230.94M
Beta (5Y monthly)-0.60
PE ratio (TTM)N/A
EPS (TTM)-0.2250
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

    VANCOUVER, Wash., January 25, 2022--Today the Board of Directors ("the Board") of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership transition plan. Effective immediately, Antonio Migliarese, currently CytoDyn’s Chief Financial Officer, has been appointed interim President. The Board of Directors terminated the employment of Nader Z. Pourhassan,

  • Business Wire

    CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

    VANCOUVER, Wash., January 13, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.

  • Business Wire

    Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced ("HTE") Subjects

    VANCOUVER, Wash., January 10, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that a research paper entitled "Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects" has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect. ScienceDirect provides